Participated · Equity · Aug 2026

PaXini develops full-stack embodied perception products—haptic chips, sensors, and multimodal data pipelines—positioning itself as an infrastructure and standards contributor for Physical AI. Over the past year the company reported near-1 million units of self-developed haptic chip consumption, and its multimodal haptic data has been adopted by leading embodied intelligence foundation model companies and major internet technology firms. PaXini says it has achieved product-market fit in the perception track and operates large-scale embodied intelligence data collection factory clusters to produce structured multimodal haptic data. Its core patents reportedly cover major global markets, and the company is building localized operations and delivery systems in North America, Japan, South Korea, and Europe. PaXini's customer matrix has penetrated core global supply chains, and the company emphasizes its role as a foundation for delivering standardized physical interaction data to embodied models. The company aims to scale global commercial deployment and deepen integration with world-class supply chains as it expands internationally.

Participated · Series B · Jun 2026

HemaCell develops cell therapeutics centered on the platelet lineage, with a flagship product described as the world's first megakaryocyte injection and a pipeline of platelet injection candidates. The company aims to address blood supply shortages and reduce adverse consequences associated with blood transfusions, while pursuing platelet-derived therapeutics for aging-related indications. HemaCell is advancing multiple clinical trials for its lead program and plans to use recent Series B proceeds to support those trials and pipeline development. Management has signaled plans for a pre-IPO fundraising within the year to build manufacturing bases and expand production capacity. Founder Zhu Fangfang stated the company will continue steady, market- and clinic-driven development and rapidly pursue capital market milestones to enable eventual product launches.

Led · Series B · Apr 2026

Syneron Bio develops macrocyclic peptide therapeutics using its proprietary, high-throughput Synova™ discovery platform. The company's pipeline is diversified across oncology, autoimmune, metabolic, and rare disease indications. Syneron Bio plans to use the Series B proceeds to further evolve and scale its intelligence-driven Synova™ platform and to accelerate progression of multiple core programs into clinical development. The financing, which strengthened the company's cash position, includes participation from global life-science funds, sovereign wealth, strategic corporates and existing shareholders. Syneron Bio highlights improving platform efficiency and success rates as central to its future discovery and development efforts. The company is headquartered in Beijing.

Led · Series A · Mar 2026

Founded in June 2022 and led by CEO Pan Weiwei, Zhongke Qingneng focuses on ultra-low-temperature technologies (below ~20K) for advanced fields such as magnetic-confinement fusion, hydrogen energy, aerospace, and quantum computing. The company has developed domestic capabilities across hardware and control software, breaking technical barriers previously dominated by foreign firms. Its proprietary helium refrigerator achieves about -269°C with 3 kW cooling capacity and is deployed at the CRAFT fusion research facility. Zhongke’s 1-ton-per-day hydrogen liquefaction unit supported Long March 8 launches and has recorded China’s longest continuous runtime, and a 5-ton-per-day unit has completed assembly and supply contracts with commercial operation targeted for September 2026. The firm intends to expand R&D and commercialize large hydrogen liquefaction plants, fusion-reactor cooling systems, and next-generation quantum low-temperature sensing platforms. The articles do not report company revenue or user metrics.

Led · Series C · Mar 2026

AIsphere develops multimodal video large models and related products, including the consumer-facing PixVerse (for overseas markets) and PaiWo AI (for domestic users). The company launched its real-time world model PixVerse R1 in January 2026, which supports 1080p real-time generation and on-the-fly video edits via natural language, and released PixVerse Game in July 2026 to apply real-time video generation to interactive entertainment. AIsphere reports that PixVerse has accumulated over 150 million global users and its PixVerse V6 model ranks on international benchmarks for text-to-video and image-to-video. Commercial partnerships and pilots include collaborations with Mango Media and enterprise partners such as Alibaba, Giant Group, China Ruiyi, BlueFocus and 37 Interactive Entertainment across short drama, animation, variety, promotional assets, interactive games and multilingual content. Financially, the company has completed multiple financings since its 2023 founding, including a March 2026 $300M C round that valued the company at $1.0B, and most recently the ¥2.98B C+ tranche led by Alibaba to fund further R&D and global expansion.